StreetInsider.com News Articles

Form 8-K SELLAS Life Sciences For: Jun 02

Tue, 02 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26588147.html

Form 8-K SELLAS Life Sciences For: Jun 02

Tue, 02 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26588147.html

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

Thu, 14 May 2026 08:00:00 -0400

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:

2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here

A.G.P.'s Annual Virtual Healthcare

SELLAS Life Sciences Group, Inc. (SLS) Tops Q1 EPS by 2c

Tue, 12 May 2026 16:41:10 -0400

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q1 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07).
For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

Form 8-K SELLAS Life Sciences For: May 12

Tue, 12 May 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260512/26477806.html

Form 8-K SELLAS Life Sciences For: May 12

Tue, 12 May 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260512/26477806.html

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –

– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –

– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –

– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –

– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –

– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –

– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –

– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –

– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –

– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –

– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –

– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –

– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –

– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –

– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –

– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –

– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –

– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –

– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –

– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –

– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –

– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 16:05:00 -0400

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –

– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –

– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –

– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5